StreetAlpha
13F holdings · Q3 2026

Parkman Healthcare Partners

Stamford, CT · files as Parkman Healthcare Partners LLC
Know the moment Parkman Healthcare Partners filesYou follow Parkman Healthcare Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1777015

Parkman Healthcare Partners reported 91 stocks worth $1.1B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PTCT (4.1%), LLY (4.0%) and MBX (3.8%). Compared with Q2 2026, the fund opened new positions in SRRK, CRL and KOD, added to PTCT, LLY and IQV, trimmed MBX, DXCM and CVS and sold out of SYK, ZBH and BCRX.

Latest filing: what Parkman Healthcare Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
27 new31 added31 trimmed12 sold outBought about $391M · sold about $226M
New 27
See all 27 →
Added 31
See all 31 →
Trimmed 31
See all 31 →
Sold out 12
See all 12 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.1B+14.0% vs last quarter
Stocks held9127 new · 12 sold out
Top 5 weight18.8%spread out
Turnover56%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
PTCT
Ptc Therapeutics Inc
$45.4M4.1%700K+265K (+61%)8 of 8
2
LLY
Eli Lilly & Co
$44.1M4.0%38K+3,119 (+9%)7 of 8
3
MBX
Mbx Biosciences Inc
$42M3.8%717K−84K (−10%)8 of 8
4
IQV
Iqvia Holdings
$39M3.5%145K+39K (+37%)6 of 8
5
DXCM
Dexcom Inc
$37.7M3.4%437K−98K (−18%)8 of 8
6
INBX
Inhibrx Biosciences Inc
$36.1M3.3%360K+103K (+40%)2 of 8
7
VRDN
Viridian Therapeutics Inc
$34.5M3.1%1.7M+297K (+22%)8 of 8
8
URGN
Urogen Pharma Ltd
$30.5M2.8%750K+576K (+331%)8 of 8
9
SRRK
Scholar Rock Hldg Corp
$26.1M2.4%540KNew position1 of 8
10
CVS
Cvs Health Corp
$24.5M2.2%286K−106K (−27%)8 of 8
🔒 81 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
SYK
Stryker Corporation
$21.4M68K
ZBH
Zimmer Biomet Hldgs Inc
$20M233K
BCRX
Biocryst Pharmaceuticals Inc
$16.2M1.6M
QURE
Uniqure NV
$9.6M208K
AMRX
Amneal Pharmaceuticals Inc
$9.4M541K

🔒 Free account: see all 12.

Reported value

last 8 quarters
$751MQ4 '24
$843MQ1 '25
$864MQ2 '25
$911MQ3 '25
$1.1BQ4 '25
$965MQ1 '26
$974MQ2 '26
$1.1BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Parkman Healthcare Partners 13F FAQ

What does Parkman Healthcare Partners own?

Parkman Healthcare Partners reported 91 stocks worth $1.1B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PTCT (4.1%), LLY (4.0%) and MBX (3.8%). The table above lists every position in the filing (the top 10 without an account).

What did Parkman Healthcare Partners buy and sell in Q3 2026?

Compared with Q2 2026: 27 new positions, 31 added to, 31 trimmed and 12 sold out. New positions include SRRK, CRL and KOD. It sold all of SYK, ZBH and BCRX.

When will Parkman Healthcare Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Parkman Healthcare Partners's portfolio worth?

The Q3 2026 filing reports $1.1B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.